Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at [email protected].
The FDA’s recent approval of Cosela to reduce the frequency of chemotherapy-induced bone marrow suppression in adults who are receiving certain types of chemotherapy for extensive-stage small cell lung cancer is a “breath of fresh air,” according to an expert.
The Food and Drug Administration’s recent approval of the first oral hormone therapy, Orgovyx, for the treatment of advanced prostate cancer has positioned the drug to become a standard of care for patients, according to an expert.
The agency granted approval to Fotivda in adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.
The US Preventive Services Task Force now recommends lowering the age and smoking history requirements for people to receive annual lung cancer screening.
The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.
If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.
On social media, CURE® recently asked its readers to share if they have experienced cancer-related fatigue and how they have dealt with it.
In honor of International Women’s Day, CURE® compiled some recent news and updates in women’s cancers that patients, survivors and caregivers may have missed.
A roundup of some of the latest news and updates for patients with lung cancer from CURE®.
In honor of Colorectal Cancer Awareness Month, CURE® compiled some recent colorectal cancer news and updates patients and survivors may have missed.
A roundup of some of the latest news and updates for patients with breast cancer from CURE®
The International Association for the Study of Lung Cancer recently joined more than 100 cancer centers and organizations in urging leading public health officials to prioritize administering the COVID-19 vaccine to cancer survivors and patients undergoing treatment for the disease.
An expert from the Roswell Park Comprehensive Cancer Center recommends that patients with cancer get whichever vaccine is available at the time they go to get vaccinated.
On social media, CURE® recently asked its readers to share what they want to hear from family and friends and what they don’t want to hear.
The Johnson & Johnson vaccine is delivered in a single dose, which is a departure from the two doses required for the already available Pfizer-BioNTech and Moderna vaccines.
A roundup of some of the latest news and updates for patients with ovarian cancer from CURE®.
Throughout the winter, the FDA has continued to approve several new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
In this episode of the “CURE Talks Cancer” podcast, we spoke with a gynecologic cancer expert about how her sister’s journey with ovarian cancer provided her with a different perspective that would lead to raising awareness for others.
Here is a list of some recent trials that launched within the cancer space in February.
A cancer diagnosis often comes with concerns of what’s next for patients. One concern is how they’re going to afford their treatments. Here, a panel of experts discuss what options are available.
There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.
On social media, CURE® recently asked its readers to share their favorite motivational or inspirational quotes. Here's what they had to share.
There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.
The Society of Breast Imaging has recommended women wait four to six weeks after receiving their second dose of a COVID-19 vaccine to get a screening mammogram. However, experts differ on whether women should wait to get a screening mammogram following their vaccine.
This week on the “CURE® Talks Cancer” podcast, we spoke with Evofem Biosciences founder and CEO Saundra Pelletier about what it was like to go through the shock of receiving a cancer diagnosis while also navigating a career, and explaining how her product, which is now FDA-approved, can help patients with cancer and survivors improve their sexual quality of life.
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
Conservative radio host Rush Limbaugh, 70, has died after receiving an advanced lung cancer diagnosis one year ago.
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.
On social media, CURE® recently asked its readers to share their thoughts on getting the HPV vaccine to help prevent certain types of cancer later in life. Here is what some of them shared.
The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.
